Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) EBIAT: 2010-2016

Historic EBIAT for Tenax Therapeutics (TENX) over the last 3 years, with Dec 2016 value amounting to -$33.9 million.

  • Tenax Therapeutics' EBIAT fell 179.72% to -$33.9 million in Q4 2016 from the same period last year, while for Dec 2016 it was -$55.6 million, marking a year-over-year increase of 63.87%. This contributed to the annual value of -$17.6 million for FY2024, which is 128.27% down from last year.
  • Tenax Therapeutics' EBIAT amounted to -$33.9 million in Q4 2016, which was down 692.20% from -$4.3 million recorded in Q3 2016.
  • Over the past 5 years, Tenax Therapeutics' EBIAT peaked at -$1.6 million during Q4 2012, and registered a low of -$117.0 million during Q2 2013.
  • For the 2-year period, Tenax Therapeutics' EBIAT averaged around -$15.6 million, with its median value being -$12.1 million (2015).
  • Examining YoY changes over the last 5 years, Tenax Therapeutics' EBIAT showed a top increase of 66.94% in 2013 and a maximum decrease of 4,376.21% in 2013.
  • Tenax Therapeutics' EBIAT (Quarterly) stood at -$1.6 million in 2012, then slumped by 4,376.21% to -$117.0 million in 2013, then reached -$12.1 million in 2015, then plummeted by 179.72% to -$33.9 million in 2016.
  • Its EBIAT stands at -$33.9 million for Q4 2016, versus -$4.3 million for Q3 2016 and -$5.4 million for Q2 2016.